Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLLGet Rating) have received a consensus recommendation of “Moderate Buy” from the six analysts that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 12 month price objective among analysts that have covered the stock in the last year is $34.00.

COLL has been the subject of several research analyst reports. StockNews.com initiated coverage on Collegium Pharmaceutical in a research note on Wednesday, October 12th. They set a “hold” rating for the company. HC Wainwright downgraded Collegium Pharmaceutical to a “neutral” rating in a research note on Monday, August 15th. Finally, Needham & Company LLC reduced their target price on Collegium Pharmaceutical from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, November 4th.

Collegium Pharmaceutical Stock Down 2.1 %

NASDAQ:COLL opened at $21.49 on Thursday. The company has a debt-to-equity ratio of 2.95, a quick ratio of 0.82 and a current ratio of 0.98. The company has a market cap of $721.46 million, a PE ratio of -17.06, a PEG ratio of 0.29 and a beta of 0.89. Collegium Pharmaceutical has a 52-week low of $14.04 and a 52-week high of $22.89. The stock has a 50-day simple moving average of $18.12 and a 200 day simple moving average of $17.47.

Insider Transactions at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 38,589 shares of the business’s stock in a transaction dated Thursday, September 15th. The stock was sold at an average price of $18.07, for a total transaction of $697,303.23. Following the sale, the executive vice president now directly owns 109,495 shares in the company, valued at $1,978,574.65. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Joseph Ciaffoni sold 1,989 shares of the company’s stock in a transaction that occurred on Friday, November 18th. The stock was sold at an average price of $22.02, for a total value of $43,797.78. Following the sale, the chief executive officer now directly owns 323,453 shares in the company, valued at $7,122,435.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Shirley R. Kuhlmann sold 38,589 shares of the stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $18.07, for a total value of $697,303.23. Following the transaction, the executive vice president now owns 109,495 shares in the company, valued at $1,978,574.65. The disclosure for this sale can be found here. Over the last three months, insiders have sold 44,928 shares of company stock worth $816,574. Insiders own 4.34% of the company’s stock.

Hedge Funds Weigh In On Collegium Pharmaceutical

Institutional investors have recently modified their holdings of the company. Assetmark Inc. raised its position in Collegium Pharmaceutical by 52.2% in the 3rd quarter. Assetmark Inc. now owns 1,676 shares of the specialty pharmaceutical company’s stock valued at $27,000 after buying an additional 575 shares during the last quarter. Mutual of America Capital Management LLC grew its stake in Collegium Pharmaceutical by 14.6% in the 2nd quarter. Mutual of America Capital Management LLC now owns 5,706 shares of the specialty pharmaceutical company’s stock valued at $101,000 after purchasing an additional 725 shares during the period. Bank of Montreal Can grew its stake in Collegium Pharmaceutical by 9.2% in the 1st quarter. Bank of Montreal Can now owns 11,850 shares of the specialty pharmaceutical company’s stock valued at $239,000 after purchasing an additional 1,001 shares during the period. Captrust Financial Advisors grew its stake in Collegium Pharmaceutical by 97.5% in the 1st quarter. Captrust Financial Advisors now owns 2,151 shares of the specialty pharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,062 shares during the period. Finally, Denali Advisors LLC grew its stake in Collegium Pharmaceutical by 76.5% in the 2nd quarter. Denali Advisors LLC now owns 3,000 shares of the specialty pharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,300 shares during the period.

About Collegium Pharmaceutical

(Get Rating)

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment.

Read More

Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.